Apogee initiates dosing in Phase 1 trial of APG777 ahead of schedule for atopic dermatitis

Apogee Therapeutics, Inc.

First participants dosed in healthy-volunteer Phase 1 trial of APG777 ahead of initial timeline.
APG777 is a novel half-life extended anti-IL-13 antibody for moderate-to-severe atopic dermatitis.
Preclinical data suggest potential for dosing every two to three months, longer than existing therapies.
Initial subcutaneous pharmacokinetic and safety data from healthy volunteers expected in mid-2024.
Apogee plans to start a randomized Phase 2 trial in moderate-to-severe AD patients in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.